Development of aptamer therapeutics

Current Opinion in Pharmacology

Volumn 10, Issue 5, 2010, Pages 557-562

  Bunka, David HJ ^a   Platonova, Olga ^a   Stockley, Peter G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDIABETIC AGENT; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; APTAMER; ARC 1905; AS 1411; BIOTIN; CARDIOVASCULAR AGENT; CHOLESTEROL; E 10030; HEPARIN; MACROGOL; NOX A 12; NOX E 36; NU 172; NUCLEIC ACID; PEGAPTANIB; RANIBIZUMAB; RB 006; RB 007; RIBOSE; SINGLE STRANDED DNA; SMALL INTERFERING RNA; STREPTAVIDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URINARY TRACT AGENT; VASCULOTROPIN 165;

ACUTE CORONARY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; BIOTECHNOLOGY; CHEMICAL MODIFICATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-HIV AGENTS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; DIABETIC NEPHROPATHIES; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; SELEX APTAMER TECHNIQUE;

EID: 77956650825     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.06.009     Document Type: Review

References (45)

1. Robertson D.L., Joyce G.F. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990, 344:467-468.
2. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
3. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
4. Sullenger B.A., Gallardo H.F., Ungers G.E., Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990, 63:601-608.
5. Missailidis S., Hardy A. Aptamers as inhibitors of target proteins. Expert Opin Ther Pat 2009, 19:1073-1082.
6. D'Amico D.J., Masonson H.N., Patel M., Adamis A.P., Cunningham E.T., Guyer D.R., Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006, 113:992-1001.
7. Wlotzka B., Leva S., Eschgfäller B., Burmeister J., Kleinjung F., Kaduk C., Muhn P., Hess-Stumpp H., Klussmann S. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci USA 2002, 99:8898-8902.
8. White R.R., Sullenger B.A., Rusconi C.P. Developing aptamers into therapeutics. J Clin Invest 2000, 106:929-934.
9. Jackson G.W., Strych U. Nucleic acid aptamers for diagnostics and therapeutics: global markets. BCC Res 2010, (Report BIO071A).
10. Dyke C.K., Steinhubl S.R., Kleiman N.S., Cannon R.O., Aberle L.G., Lin M., Myles S.K., Melloni C., Harrington R.A., Alexander J.H., et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006, 114:2490-2497.
11. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5:123-132.
12. Jellinek D., Green L.S., Bell C., Janjić N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994, 33:10450-10456.
13. de Smidt P.C., Le Doan T., de Falco S., van Berkel T.J. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res 1991, 19:4695-4700.
14. Mayer G. The chemical biology of aptamers. Angew Chem Int Ed Engl 2009, 48:2672-2689.
15. Kaur G., Roy I. Therapeutic applications of aptamers. Expert Opin Investig Drugs 2008, 17:43-60.
16. Sousa R., Padilla R. A mutant T7 RNA polymerase as a DNA polymerase. EMBO J 1995, 14:4609-4621.
17. Chelliserrykattil J., Ellington A.D. Evolution of a T7 RNA polymerase variant that transcribes 2'-O-methyl RNA. Nat Biotechnol 2004, 22:1155-1160.
18. Beigelman L., McSwiggen J.A., Draper K.G., Gonzalez C., Jensen K., Karpeisky A.M., Modak A.S., Matulic-Adamic J., DiRenzo A.B., Haeberli P., et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 1995, 270:25702-25708.
19. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., Janjić N. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998, 273:20556-20567.
20. Boomer R.M., Lewis S.D., Healy J.M., Kurz M., Wilson C., McCauley T.G. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides 2005, 15:183-195.
21. Dougan H., Lyster D.M., Vo C.V., Stafford A., Weitz J.I., Hobbs J.B. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol 2000, 27:289-297.
22. Green L.S., Jellinek D., Bell C., Beebe L.A., Feistner B.D., Gill S.C., Jucker F.M., Janjić N. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 1995, 2:683-695.
23. Tucker C.E., Chen L.S., Judkins M.B., Farmer J.A., Gill S.C., Drolet D.W. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 1999, 732:203-212.
24. Drolet D.W., Nelson J., Tucker C.E., Zack P.M., Nixon K., Bolin R., Judkins M.B., Farmer J.A., Wolf J.L., Gill S.C., Bendele R.A. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000, 17:1503-1510.
25. Chaloin L., Lehmann M.J., Sczakiel G., Restle T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 2002, 30:4001-4008.
26. Chen C.H., Dellamaggiore K.R., Ouellette C.P., Sedano C.D., Lizadjohry M., Chernis G.A., Gonzales M., Baltasar F.E., Fan A.L., Myerowitz R., Neufeld E.F. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 2008, 105:15908-15913.
27. Lupold S.E., Hicke B.J., Lin Y., Coffey D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002, 62:4029-4033.
28. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006, 24:1005-1015.
29. Zhou J., Swiderski P., Li H., Zhang J., Neff C.P., Akkina R., Rossi J.J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009, 37:3094-3109.
30. Rusconi C.P., Scardino E., Layzer J., Pitoc G.A., Ortel T.L., Monroe D., Sullenger B.A. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002, 419:90-94.
31. Becker R.C., Chan M.Y. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. Curr Opin Mol Ther 2009, 11:707-715.
32. Mongelard F., Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr Opin Mol Ther 2010, 12:107-114.
33. Klussmann S., Nolte A., Bald R., Erdmann V.A., Fürste J.P. Mirror-image RNA that binds D-adenosine. Nat Biotechnol 1996, 14:1112-1115.
34. NOXXON website press release: NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36. October 12, 2009 (). http://www.noxxon.com/.
35. NOXXON website press release: NOXXON announces the completion of the first-in-human clinical trial with Spiegelmer® NOX-A12. May 3, 2010 (). http://www.noxxon.com/.
36. Dey A.K., Griffiths C., Lea S.M., James W. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 2005, 11:873-884.
37. Dey A.K., Khati M., Tang M., Wyatt R., Lea S.M., James W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 2005, 79:13806-13810.
38. Nozaki M., Raisler B.J., Sakurai E., Sarma J.V., Barnum S.R., Lambris J.D., Chen Y., Zhang K., Ambati B.K., Baffi J.Z., Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006, 103:2328-2333.
39. Bates P.J., Kahlon J.B., Thomas S.D., Trent J.O., Miller D.M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999, 274:26369-26377.
40. Stuart R.K., Stockerl-Goldstein K., Cooper M., Devetten M., Herzig R., Medeiros B., Schiller G., Wei A., Acton G., Rizzieri D. Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). J Clin Oncol (Meeting Abstracts) 2009, 27:7019.
41. Ophthotech website press release: Ophthotech enrolls its first patient in a randomized, controlled phase II study of E10030 in macular degeneration. April 26, 2010 (). http://www.ophthotech.com/news.
42. Maasch C., Buchner K., Eulberg D., Vonhoff S., Klussmann S. Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications. Nucleic Acids Symp Ser 2008, 52:61-62.
43. Wagner-Whyte J., Khuri S.F., Preiss J.R., Kurz J.C., Olson K., Hatala P., Boomer R.M., Fraone J.M., Brosnan N., Makim A., et al. Discovery of a potent, direct thrombin inhibiting aptamer. J Thromb Haemost (ISTH Congress abstracts). 2007.
44. Chan M.Y., Rusconi C.P., Alexander J.H., Tonkens R.M., Harrington R.A., Becker R.C. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 2008, 6:789-796.
45. Rusconi C.P., Roberts J.D., Pitoc G.A., Nimjee S.M., White R.R., Quick G., Scardino E., Fay W.P., Sullenger B.A. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004, 22:1423-1428.